Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8409MR)

This product GTTS-WQ8409MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8409MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9928MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ4065MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ12178MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ12671MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ4256MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ13026MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ13010MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ6533MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CX-191
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW